Comparing catheter ablation and anti-arrhythmic drugs for treating ventricular tachycardia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of catheter ablation compared to anti-arrhythmic drugs (AADs) in patients with recurrent ventricular tachycardia (VT) due to structural heart disease. The study aims to determine which treatment option better reduces the recurrence of VT and improves patient quality of life. Patients eligible for the trial must have experienced at least one episode of sustained VT in the past six months. The trial will be conducted at multiple hospitals in Australia, focusing on patients with specific heart conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Patients will be eligible for inclusion if they have:

1. ≥1 prior episode of sustained VT in the prior 6 months;

   1. Spontaneous VT: ≥1 episode of monomorphic VT treated by anti-tachycardia pacing (ATP) and/or internal shock by an ICD; lasting ≥30 seconds in the absence of intra-cardiac device therapy that could either be self-terminating or require reversion by pharmacological therapy or external cardioversion;
   2. Spontaneous VT: ≥1 episode of sustained spontaneous monomorphic VT lasting ≥30 seconds documented on Holter, ECG, Loop recorder or other cardiac monitoring device that could either be self-terminating or require reversion by pharmacological therapy or external cardioversion;
   3. Inducible VT: with syncope or palpitations - inducible VT defined as sustained monomorphic VT of CL ≥200 ms lasting for ≥10 s during a cardiac electrophysiology study (note with 4 extrastimuli with or without provocation with isoprenaline);
2. Already a recipient of an implanted cardiac device such as a pacemaker, defibrillator or a cardiac resynchronisation therapy device and/or is indicated to receive one given a new diagnosis of structural heart disease, based on current guideline recommendations;
3. Aged ≥18 years.

Exclusion Criteria:

Patients will be excluded if they are:

1. Unable or unwilling to provide informed consent or patients physician feels there is not significant equipoise to justify randomisation;
2. Women who are pregnant, breast feeding;
3. Medical illness with an anticipated life expectancy \<3 months;
4. Unable to complete study procedures or unwilling to be followed up;
5. Have a concomitant illness, physical impairment or mental condition which in the opinion of the study team/ primary care physician could interfere with the conduct of the study including outcome assessments;
6. Known channelopathy such as long QT, short QT, Brugada syndrome, catecholaminergic polymorphic VT;
7. Known prior diagnosis of no structural heart disease, or idiopathic ventricular arrhythmia.

Where it's running

• Blacktown Hospital
  Blacktown, New South Wales, Australia Recruiting
• Royal Prince Alfred Hospital
  Camperdown, New South Wales, Australia Recruiting
• Nepean Hospital
  Kingswood, New South Wales, Australia Recruiting
• John Hunter Hospital
  New Lambton Heights, New South Wales, Australia Recruiting
• Royal North Shore Hospital
  Saint Leonards, New South Wales, Australia Recruiting
• Westmead Hospital
  Westmead, New South Wales, Australia Recruiting

Study contacts

• Principal investigator: Saurabh Kumar, MBBS, PhD — Western Sydney Local Health District
• Study coordinator: Saurabh Kumar, MBBS, PhD
• Email: saurabh.kumar@health.nsw.gov.au
• Phone: +61288908140

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Registry for hereditary cardiovascular diseases in Brazil

  This study is trying to create a registry of Brazilian patients with hereditary heart diseases to see how common certain genetic changes are in people with these conditions.

  Recruiting at 27 sites Hospital do Coracao · Rio Branco, Acre and 26 other locations · NCT06546137

• Using SBRT to treat ventricular tachycardia

  This study is testing if a special type of radiation therapy can help patients with ventricular tachycardia who haven't found relief from other treatments.

  Recruiting Nova Scotia Health Authority · Halifax, Nova Scotia · NCT04162171

• Registry and biobank for arrhythmogenic ventricular cardiomyopathy

  This study is trying to gather information and samples from people with arrhythmogenic ventricular cardiomyopathy and their families to better understand the genetic causes of the condition and improve early diagnosis for those at risk.

  Recruiting at 2 sites Mayo Clinic · Rochester, Minnesota and 1 other locations · NCT03049254

• AI-powered ECG to help diagnose and locate tachycardia in patients with PSVT, WPW, PVC, or VT

  A multicenter registry test whether an AI-enabled ECG analysis can help diagnose and localize tachycardia in adults with certain arrhythmias.

  Recruiting Inha University Hospital · Incheon, Incheon · NCT07859020

• DuoVT PFA System for Treating Ventricular Tachycardia

  This study tests whether the DuoVT Pulsed Field Ablation system can safely and effectively treat Ventricular Tachycardia in people with ischemic heart disease.

  Recruiting at 2 sites Abbott Medical Devices · Split, Dalmtia and 4 other locations · NCT07706712

• Sphere VT: Using Sphere-9 Catheter and Affera System to treat recurrent scar-related ventricular tachycardia

  This study tests the Sphere-9 catheter and Affera mapping and ablation system in adults with recurring scar-related ventricular tachycardia after a prior heart attack.

  Recruiting at 5 sites Medtronic Cardiac Ablation Solutions · Littleton, Colorado and 6 other locations · NCT07585968

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.